Advertisement

Topics

Daiichi-Sankyo Company Profile

10:32 EDT 22nd June 2018 | BioPortfolio


News Articles [121 Associated News Articles listed on BioPortfolio]

Daiichi Sankyo to restructure vaccines subsidiary

Daiichi Sankyo is set to restructure its wholly-owned Kitasato Daiichi Sankyo Vaccine subsidiary into a specialised manufacturing division to enhance...Read More... The post Daiichi Sankyo to restruct...

Daiichi Sankyo to develop new inflammatory disease drugs

Daiichi Sankyo has formed a new consortium focused on research and discovery of medicines over a period of five years...Read More... The post Daiichi Sankyo to develop new inflammatory disease drugs a...

BRIEF—Daiichi Sankyo US reorganization means 280 job cuts

Japanese pharma major Daiichi Sankyo says it will reorganize its US commercial organization as it continues…

Daiichi Sankyo reports on results for leukemia candidate

Daiichi Sankyo's quizartinib, a drug being tested in a Phase III trial as a treatment for patients with relapsed or refractor -More- 

Daiichi Sankyo Presents Phase 3 ENLIVEN Study of Pexidartinib, Demonstrating Statistically Significant Clinical Improvement Across Multiple Endpoints in Patients with Tenosynovial Giant Cell Tumor

Tokyo, Basking Ridge, NJ, and Munich – (June 4, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the phase 3 ENLIVEN study showed a statistically significan...

EHA 2018: pivotal Phase III data for Daiichi Sankyo’s quizartinib

Daiichi Sankyo’s pivotal data presentation at this year’s European Hematology Association (EHA) annual meeting showed that its FLT3 inhibitor quizartinib...Read More... The post EHA 2018: pivotal ...

Daiichi Sankyo’s Ken Truitt Joins ImmusanT as Chief Medical Officer

Ken Truitt has been appointed chief medical officer of immune drug developer ImmusanT. Truitt comes to the Cambridge, MA, biotech from Daiichi Sankyo, where he was senior vice president for internal m...

BRIEF—Hitachi and Daiichi Sankyo reach manufacturing accord

Chūō, Tokyo-based pharmaceutical firm Daiichi Sankyo has awarded Hitachi Chemical a contract to manufacture…

Drugs and Medications [11 Associated Drugs and Medications listed on BioPortfolio]

Benicar [Daiichi Sankyo, Inc]

These highlights do not include all the information needed to use Benicar safely and effectively. See full prescribing information for Benicar. Benicar (olmesartan medoxomil) tablets Initial U.S. Appr...

Evoxac capsules(cevimeline hydrochloride) [Daiichi Sankyo Pharma Development]

EVOXAC Capsules(cevimeline hydrochloride)

Azor [Daiichi Sankyo, Inc.]

These highlights do not include all the information needed to use AZOR safely and effectively. See full prescribing information for AZOR. AZOR (amlodipine and olmesartan medoxomil) tablets, for oral u...

Welchol [Daiichi Sankyo, inc.]

These highlights do not include all the information needed to use Welchol safely and effectively. See full prescribing information for Welchol. Welchol (colesevelam hydrochloride) Tablet, Film Coated,...

Quixin [Vistakon Pharmaceuticals LLC]

QUIXIN (levofloxacin ophthalmic solution) 0.5%

PubMed Articles [20 Associated PubMed Articles listed on BioPortfolio]

Assessment of medium-term cardiovascular disease risk after Japan's 2011 Fukushima Daiichi nuclear accident: a retrospective analysis.

To assess the medium-term indirect impact of the 2011 Fukushima Daiichi nuclear accident on cardiovascular disease (CVD) risks and to identify whether risk factors for CVD changed after the accident.

Roles of children and their parents in the reduction of radiation risk after the 2011 Fukushima Daiichi Nuclear Power Plant accident.

On March 11, 2011, Japan experienced its largest recorded earthquake with a magnitude of 9.0. The resulting tsunami caused massive damage to the Fukushima Daiichi Nuclear Power Plant reactors, and the...

Long-term outcomes of patients evacuated from hospitals near the Fukushima Daiichi nuclear power plant after the Great East Japan Earthquake.

After the accident of the Fukushima Daiichi nuclear power plant due to the Great East Japan Earthquake in March 2011, the Japanese government issued a mandatory evacuation order for people living with...

Radiocesium contamination in house dust within evacuation areas close to the Fukushima Daiichi nuclear power plant.

Outdoor decontamination efforts have been ongoing since the Fukushima Daiichi nuclear power plant (FDNPP) accident; however, little is known about indoor contamination. Therefore, house dust was sampl...

131I DOSE ESTIMATION FROM INTAKE OF TAP WATER IN THE EARLY PHASE AFTER FUKUSHIMA DAIICHI NUCLEAR POWER PLANT ACCIDENT.

In March 2011, the Fukushima Daiichi Nuclear Power Plant Accident occurred and a large amount of radionuclides was released. To study its effect, we estimated the internal exposure due to intake of ta...

Clinical Trials [12 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar® 40 mg Tablets of Daiichi Sankyo Inc., USA. Dosing periods of studies were ...

Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma

This study evaluates the non-inferiority of the new transdermal patch dosage form containing loxoprofen sodium (100 mg - Daiichi-Sankyo) in comparison with oral Loxonin® (60 mg tablet - D...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablet Under Fasting Conditions

Subjects to compare the single dose bioavailability of Torrent's Olmesartan Medoxomil Tablets 40 mg and Benicar 40 mg Tablets of Daichi Sankyo Inc. USA. Dosing periods of studies were sepa...

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Hong Kong proposed this non-interventional study (NIS)...

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Thailand proposed this non-interventional study (NIS) ...

Companies [28 Associated Companies listed on BioPortfolio]

DAIICHI SANKYO EUROPE GmbH and SHARE

DAIICHI SANKYO is a global pharmaceutical company that focuses on researching and marketing innovative medications. The company was created in 2005 through the merger of two traditional Japanese e...

Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. ...

Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited, established in 2005 after the joint share transfer of two leading century-old Japanese pharmaceutical companies, is continuously generating innovative drugs that e...

ArQule, Inc. and Daiichi Sankyo Company, Limited

On December 19, 2008, ArQule and Daiichi Sankyo, Co., Ltd. signed a license, co-development and co-commercialization agreement to co-develop tivantinib in the U.S., Europe, South ...

Daiichi-Sankyo

More Information about "Daiichi-Sankyo" on BioPortfolio

We have published hundreds of Daiichi-Sankyo news stories on BioPortfolio along with dozens of Daiichi-Sankyo Clinical Trials and PubMed Articles about Daiichi-Sankyo for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Daiichi-Sankyo Companies in our database. You can also find out about relevant Daiichi-Sankyo Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record